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Abstract
Background: Suboptimal diagnostics for pulmonary tuberculosis (PTB) drives use of ‘trial-of-antibiotics (non-
tuberculosis)’ in an attempt to distinguish PTB patients from those with bacterial lower respiratory tract
infection (LRTI). The underlying assumption—that patients with LRTI will report ‘response’ to broad-spectrum
antibiotics, while those with PTB will not—has minimal evidence base for such a widely used intervention.
Numerous potential causes of misclassification include bacterial super-infection of active PTB, placebo effect,
and antimicrobial resistance (AMR). The main aim of this systematic review is to collate available evidence on
the performance of trial-of-antibiotics as a diagnostic test and to explore the timing, interpretation, and
decision-making process.
Methods: We will search MEDLINE, Embase, and Global Health using the Ovid platform for published studies
that recruited adults being investigated for PTB, performed trial-of-antibiotics accompanied by mycobacteriological
investigations, and reported both diagnostic test outcomes at the individual level. Following article selection, two
authors will independently review titles and abstracts against eligibility criteria then perform full-text screening and
extraction into a spreadsheet. We will conduct a risk of bias assessment at the level of the study using QUADAS-2
(University of Bristol) tool that assesses diagnostic evaluation work in four domains: (1) patient selection, (2) the index
test, (3) the reference standard, and (4) patient flow and timing of tests. We will perform a narrative synthesis and,
where possible, meta-analyses addressing our primary outcome. Our protocol adheres to the standards recommended
by the PRISMA-P.
Discussion: Pooling all available evidence on the accuracy, approach, and interpretation of results of trial-of-antibiotics
in the context of PTB diagnosis will meet an urgent need, considering the widespread utilisation and potential for
antimicrobial resistance. We therefore believe that our findings will have impact on policy and that they will inform the
design of future detailed investigations into this important diagnostic approach.
Systematic review registration: PROSPERO CRD42017083915
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Background
Limitations of current diagnostics remain a challenge in
the fight against tuberculosis (TB), a leading cause of in-
fectious disease mortality with 10.4 million new cases
and 1.8 million deaths annually [1]. To complement the
suboptimal diagnostics, standard diagnostic algorithms
in resource-limited settings include a ‘trial-of-antibio-
tics.’ This is a course of broad-spectrum antibiotics, with
negligible Mycobacterium tuberculosis activity, given to
patients with symptoms such as cough in order to ‘rule--
out’ or ‘rule in’ TB [2–4]. Patients with negative sputum
mycobacteriology who respond to the antibiotic treat-
ment are considered TB negative, while those who re-
main symptomatic are deemed likely to have TB and
undergo further evaluations leading on to receiving TB
treatment.
Approximately 26.5 million antibiotics courses are pre-
scribed in the course of diagnosis of the 5.3 million smear
negative TB registrations per annum [7]. This estimate is
based on assuming an average of 5 antibiotic courses per
sputum-negative treatment initiation, with 2 courses given
to the patients before TB treatment [5] and the other 3
courses accounting for patients whose symptoms resolved
and TB was ruled out [6]. Despite this widespread use,
there has been no previous systematic review of the diag-
nostic performance of trial-of-antibiotics. The objective of
this review is to assess existing evidence for the diagnostic
sensitivity and specificity of using trial-of-antibiotics com-
pared to sputum culture for TB diagnosis.
Other important evidence gaps on this subject include
the choice of non-TB antibiotics (except for avoidance
of those with known anti-TB activity), timing of the
treatment, number of trials, the definition of treatment
response, and the exact management after knowing the
treatment outcome. Lack of consolidated evidence in
these may be the source of the variations of implementa-
tion of trial-of-antibiotics across national programs. We
will in this review consolidate existing evidence related
to these gaps as our secondary objectives.
Research question
Our study will address the following Population, Index
test, Reference test, Outcome (PIRO) question.
Objectives
Primary objective
Our primary objective is to determine the sensitivity and
specificity of using a trial-of-antibiotics compared to
sputum mycobacteriology for diagnosis of pulmonary
TB (PTB).
Secondary objectives
Our secondary objectives are as follows:
 To describe the timing of prescription of the trial-
of-antibiotics in TB diagnostic algorithms as re-
ported in included articles
 To describe the type, duration, and number of
prescriptions of routine oral antibiotics
 To establish how response to trial-of-antibiotics is
interpreted and the decision-making process following
positive or negative results
Methods
Eligibility criteria
We will include studies in any language published after
1993 that recruited adults being investigated for PTB
and performed and reported outcomes of both
trial-of-antibiotics and mycobacteriology investigations
as part of their diagnostics work up. We will define
mycobacteriology tests as any laboratory test that identi-
fies evidence of MTB from a sputum sample. There is
no defined reference mycobacteriology diagnostic test
for MTB; each of the available tests has considerable
flaws. Considering the time period of the review, we
expect smear microscopy, smear microscopy using a
fluorescent microscope, Cepheid GeneXpert, and myco-
bacterial culture. The guiding PIRO (population, index
test, reference test and Outcome) framework for the re-
search question is as presented in Table 1 below.
Information sources and search strategy
We will search for studies meeting the eligibility criteria in
MEDLINE, Embase, and Global Health using the Ovid
platform. We will use the search strategy presented in
Table 2 below to retrieve studies from the databases. We
have chosen to include studies published after 1993 when
the World Health Organization declared tuberculosis as a
‘global emergency’ greatly increasing funding and inter-
national commitment to tuberculosis research, manage-
ment, and control efforts.
In Table 2 below, we have presented our search strat-
egy for MEDLINE, which has also been adapted for
Embase and Global Health (see Additional file 1). This
search strategy was reviewed by an information retrieval
expert from the LSHTM library (Table 2). After com-
pleting the search in these databases, we will export re-
sults to Endnote X8 and remove all duplicates. We will
also include all relevant articles identified from citations
and reference lists of all included articles.
Study selection and data extraction
Investigator TD will implement the search strategy, and
then, investigators TD and MN will independently sift
through titles and abstracts of the resulting papers against
the eligibility criteria. TD and MN will independently as-
sess full texts of the included papers for eligibility using
the above criteria. The main reason for non-inclusion at
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the full-text stage will be documented. Investigator
KF will resolve any disagreements in eligibility. Inves-
tigators TD and MN will then extract data from all
the eligible papers into an excel spreadsheet. Should
we identify multiple publications from the same
study, we will report data from one.
For studies with missing or incomplete information for
meta-analysis, we will contact the authors by using the
contact information provided in the publications. When
attempts to contact the authors have not been successful,
such studies will be excluded from the meta-analysis.
Quality assessment
We will conduct a risk of bias assessment at the level of
the study using the QUADAS-2 (University of Bristol),
the recommended tool for evaluating primary studies for
the inclusion in systematic reviews for diagnostic accur-
acy. The tool, provided in Additional file 2, has four do-
mains evaluating (1) patient selection, (2) the index test,
(3) the reference standard, and (4) patient flow and tim-
ing of tests. Assessment is done with respect to risk of
bias and applicability of results.
Data analysis
We will provide a narrative synthesis of our results sum-
marising the key findings, reporting on their consistency
and quality, and identifying evidence gaps or limitations.
We will perform a meta-analysis for sensitivity and specifi-
city of trial-of-antibiotics against mycobacteriology tests
for all studies providing true positives, false positives, true
negatives, and false negatives. Our sensitivity-specificity
joint modelling will require each study to provide data for
both sensitivity and specificity.
We will utilise the MIDAS module [7] in Stata statis-
tical software (version 15.0; Stata Corporation, College
Station, TX, USA), to carry out the meta-analysis. We
will also report point estimates and 95% confidence in-
tervals, for sensitivity and specificity of trial-of-antibiotics
versus mycobacteriology for each study and for pooled
data, using bivariate random effects meta-analysis. We
will report these results using a forest plot and plot a
summary receiver operating characteristics (SROC)
curve. We will examine clinical utility of trial-of-antibiotics
using a Fagan plot.
Table 1 Research question
Population Adult patients with respiratory symptoms
Index test Trial-of-antibiotics (any course of broad-spectrum antimicrobial given with the goal of ruling out TB in a symptomatic adult)
Reference test Any mycobacteriology test (we expect smear microscopy, smear microscopy using a fluorescent microscope, Cepheid GeneXpert,
and mycobacterial culture)
Outcome Proportion of mycobacteriology-positive or mycobacteriology-negative participants correctly identified by trial-of-antibiotics (sensitivity
and specificity)
Design Cross-sectional, cohort, and randomised controlled studies
Table 2 Search strategy for MEDLINE using Ovid platform
Search in Ovid MEDLINE
Search line Search terms
Part 1 Defining study population
1. exp Tuberculosis/
2. tuberculosis.mp.
3. (suspect* adj3 (TB or Tuberculosis)).mp.
4. (presumpt* adj3 (TB or Tuberculosis)).mp.
5. (probabl* adj3 (TB or Tuberculosis)).mp.
6. exp Cough/
7. tb.mp.
8. (suspect* adj3 (TB or Tuberculosis)).mp.
9. or/1-8
Part 2 Defining study intervention
1. (Antibiotic* adj3 trial).mp.
2. antibiotic*.mp.
3. Anti-Bacterial Agents/
4. (oral* adj3 antibiotic*).mp.
5. (amox?cillin or erythromycin or azithromycin or
doxycyclin* or Vibramycin or clavulanic acid or co-
amoxiclav).mp.
6. or/10-14
Part 3 Defining study outcome
1. exp “Sensitivity and Specificity”/
2. sensitivity.mp.
3. specificity.mp.
4. accuracy.mp.
5. exp “Predictive Value of Tests”/
6. ((positive or negative) adj2 predictive value).mp.
7. (ppv or npv).mp.
8. or/16-22
Part 4 Subject combinations
1. 9 and 15 (population and intervention)
2. 23 and 24 (Population and intervention and outcome)
Part 5 Applying pre-defined limits
1. limit 25 to yr=“1993 -Current”
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Subgroup analyses
We will perform the following subgroup analyses:
1. Geographical location. While sensitivity and
specificity cannot be influenced by disease
prevalence, in the case of trial-of-antibiotics,
causes of symptoms and antibiotic susceptibility
may vary from place to place. We will assess
performance of trial-of-antibiotics versus
mycobacteriology in the following regions: (1)
sub-Saharan Africa, (2) Asia, and (3) South
America.
2. Type of reference test. The goal of a reference
standard test is to provide error-free classification
of the disease outcome presence or absence. Since
for TB, there is no test that truly meets this
definition, the performance of trial-of-antibiotics
may vary depending on the inherent properties
of each reference standard. We will assess the
performance of trial-of-antibiotics versus
mycobacteriology in the following regions: (1)
studies using microscopy-based approaches, (2)
studies using MTB culture, and (3) studies using
Cepheid GeneXpert.
Assessment for heterogeneity and publication bias
We will assess the extent of heterogeneity of diagnostic
specificity and sensitivity using Cochran Q2 and I2 tests.
Diagnostic specificity and sensitivity forest plots and a
bivariate boxplot will provide visual representation of
the extent of heterogeneity.
There is limited consensus on the most appropriate
approach for identifying evidence of publication bias in
studies of diagnostic performance. We have decided to
use the Deeks funnel plot [8], where the inverse of the
square root of the effective sample size is plotted against
the diagnostic odds ratio, and publication bias is deemed
absent if the plot achieves a funnel shape.
Result presentation and dissemination
For individual studies, we will present data as follows:
author, year, country, whether a country has a low or
high TB burden, population, sample size, design, TB
reference standard, and results (sensitivity and specifi-
city). We will present the results of our study selec-
tion using the approach prescribed by the Preferred
Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) [9].
We will prepare a manuscript, which we will submit
for publication in a peer-reviewed journal. This work
will also form part of a PhD thesis for TD, which he will
submit to the London School of Hygiene & Tropical
Medicine (LSHTM).
Protocol and registration
We registered this systematic review protocol with the
International Prospective Register of Systematic Reviews
(PROSPERO), registration number CRD42017083915.
Discussion
Our systematic review will be, to our knowledge, the first
to pool evidence on the approach, implementation, and
accuracy of using a trial-of-antibiotics for the diagnosis of
tuberculosis. Trial-of-antibiotics is an integral component
of diagnostic algorithms in low- and middle-income coun-
tries which, despite leading to 30 million empirical anti-
biotic prescriptions per annum, remains without strong
evidence basis. Our findings therefore have high potential
to prompt policy review as well as potentially stimulating
funders and researchers to consider future studies into
this component of the diagnostic algorithm.
Additional files
Additional file 1: Search strategy for Embase and Global Health in Ovid
Embase. (DOCX 18 kb)
Additional file 2: Data extraction form. (DOCX 82 kb)
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